Diversity, Equity and Inclusion:

As members of PhRMA, we believe improving human life means celebrating human diversity
Hands of many colors forming a circle


We are committed to promoting a collaborative, innovative and inclusive work environment at which everyone can contribute to their fullest potential.

We appreciate one another's differences and strengths and are proud to be an Equal Opportunity Employer. Incyte values diversity of backgrounds and perspectives. 

Incyte is a proud corporate member of the Healthcare Businesswomen’s Association. This membership provides employees with discounted membership, networking events and training opportunities

Hands of many colors forming a circle

Clinical Trial Diversity

Incyte is committed to taking the necessary steps to encourage diversity in our own clinical trials. To that end, we intend to explore opportunities to increase racial and ethnic diversity in clinical trials through our Clinical Trial Diversity Working Group. We are making it a priority to remove participation barriers, improve diversity, and pave the way to a healthier future for everyone.

Hands of many colors forming a circle

Executive Team Diversity

Our Executive Management team is made up of a diverse group of very experienced individuals who are representative of our global outlook and the multicultural nature of the pharmaceutical industry.
As an illustration of the diversity of thought and backgrounds of our Executive Management team, nine of the twelve members were born outside the U.S. In addition, 25% of our Executive Leadership Team positions are currently filled by women and 33% of our Executive Leadership Team is diverse.

Environmental Sustainability:

As members of PhRMA, we believe a healthy environment is essential for improving human life
View of Earth with a plant growing from the top

Environmental Targets

Operationally carbon neutral by 2025 (Scopes 1 and 2 emissions)

Achieve Green Globes Certification for a newly constructed building at U.S. Headquarters after completion

Include reporting under the Task Force on Climate-related Financial Disclosures (TCFD) Framework by 2023

Complete the transition of the Field Fleet to hybrid and electric vehicles by 2025

View of Earth with a plant growing from the top


We are proud to announce that, as of January 1, 2021, our U.S. headquarters’ electricity is 100% renewably sourced from the purchase and retirement of renewable energy certificates. In addition, we achieved three out of a possible four Green Globes in connection with our recent Green Globes Certification for Building 1815 at our U.S. headquarters, which demonstrates outstanding success in resource efficiency, reducing environmental impacts and improving occupant wellness.
View of Earth with a plant growing from the top


Incyte has developed plans to consider facility impact on biodiversity and land when designing new buildings and renovating existing facilities, including

• A Storm Water Pollution Prevention Plan, which establishes and communicates awareness of appropriate practices associated with pollution prevention techniques and materials to divert or prevent storm water contamination

• Spill response procedures to be used in the event of a hazardous chemical spill

• A waste disposal program that outlines procedures for disposal of hazardous waste in compliance with the Federal Resource Conservation and Recovery Act

Access & Affordability:

As members of PhRMA, we believe that living our mission of improving human life relies on broad access to medicines
A heart, a hospital Icon and a speech bubble forming a circle around an icon of a person

Oncology Patient Support and Resources

The Incyte Charitable Giving Foundation will provide general operating or program support to organizations that offer services or resources to help oncology patients and their families in Delaware cope with their disease/condition.
A heart, a hospital Icon and a speech bubble forming a circle around an icon of a person


Our IncyteCARES (Connecting to Access, Reimbursement, Education and Support) program supports eligible privately or uninsured patients in the U.S. before and during applicable treatment with Jakafi® (ruxolitinib) and Pemazyre® (pemigatinib)1 through ongoing support and education with dedicated nurses, and patient access coordinators. IncyteCARES services include copay/coinsurance assistance for eligible commercially insured patients, free product assistance for eligible patients who are uninsured or who experience temporary coverage delays, reimbursement support through benefit verifications and clinical education support to patients about their condition and use of the medicine they are receiving.

A heart, a hospital Icon and a speech bubble forming a circle around an icon of a person

My MISSION Support

Through My Mission Support, Incyte and MorphoSys are committed to supporting patients throughout their treatment journeys before and during treatment with Monjuvi® (tafasitamab-cxix). My Mission Support is a patient support program offering financial assistance, ongoing education and other resources to eligible patients who are prescribed Monjuvi® (tafasitamab-cxix) in the United States.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.